» Articles » PMID: 11751698

Angiotensinogen Gene Core Promoter Variants and Non-modulating Hypertension

Overview
Journal Hypertension
Date 2001 Dec 26
PMID 11751698
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Non-modulation has been suggested as a possible intermediate phenotype defining a subgroup of genetic hypertension. The trait is characterized by an attenuated response of renal blood flow and/or aldosterone to angiotensin (Ang) II. We tested the hypothesis that functional polymorphisms of the core promoter of the angiotensinogen gene are associated with non-modulation. Fifty-six young, white, male, untreated hypertensive patients and 65 age-matched normotensive volunteers were genotyped for 3 known functional variants of the angiotensinogen core promoter. All subjects were infused with 2 doses (0.5 and 3 ng/kg per minute) of Ang II while they were on a high sodium diet (250 mmol/d). The blood pressure, renal plasma flow, and aldosterone responses to Ang II were not affected by the -6 G/A polymorphism. The -20 A/C variant had no significant effects on the blood pressure or renal hemodynamic response to Ang II. However, the aldosterone response to both doses of Ang II was significantly decreased in -20 C allele carriers compared with -20 AA homozygotes in a multivariate analysis. The -18 T allele was not detected in our population, and there was a linkage dysequilibrium between -20 C and -6 A: -20 C almost exclusively occurred on the -6 A allele. Haplotype analysis indicated that the -20 C/-6 A haplotype but not the -20 A/-6 A haplotype was associated with a decreased aldosterone response to Ang II. We conclude that the -20 C variant or the -20 C/-6 A haplotype of the angiotensinogen core promoter is associated with a blunted aldosterone response to Ang II and may thus contribute to the non-modulating phenotype.

Citing Articles

Association of angiotensinogen gene SNPs and haplotypes with risk of hypertension in eastern Indian population.

Purkait P, Halder K, Thakur S, Ghosh Roy A, Raychaudhuri P, Bhattacharya S Clin Hypertens. 2017; 23:12.

PMID: 28361007 PMC: 5371191. DOI: 10.1186/s40885-017-0069-x.


Allele-specific expression of angiotensinogen in human subcutaneous adipose tissue.

Park S, Lu K, Liu X, Chatterjee T, Rudich S, Weintraub N Hypertension. 2013; 62(1):41-7.

PMID: 23648704 PMC: 3718031. DOI: 10.1161/HYPERTENSIONAHA.113.01330.


A-6G and A-20C polymorphisms in the angiotensinogen promoter and hypertension risk in Chinese: a meta-analysis.

Gu W, Liu J, Niu Q, Wang H, Lou Y, Liu K PLoS One. 2012; 6(12):e29489.

PMID: 22216295 PMC: 3247271. DOI: 10.1371/journal.pone.0029489.


Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: the importance of haplotypes.

Watkins W, Hunt S, Williams G, Tolpinrud W, Jeunemaitre X, Lalouel J J Hypertens. 2009; 28(1):65-75.

PMID: 19770777 PMC: 3025818. DOI: 10.1097/HJH.0b013e328332031a.


Effect of the angiotensinogen genotype on experimental hypertension in mice.

Handtrack C, Cordasic N, Klanke B, Veelken R, Hilgers K J Mol Med (Berl). 2007; 85(4):343-50.

PMID: 17333097 DOI: 10.1007/s00109-007-0166-5.